J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on October 23.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chris Schott has given his Buy rating due to a combination of factors that highlight Gilead Sciences’ strong position in the HIV and PrEP markets. The launch of Yeztugo has been promising, with early physician feedback indicating a positive reception and significant potential for market expansion. The drug is gaining traction among a diverse patient base, which suggests a broad market opportunity and the potential to become a leading option in the PrEP space.
Additionally, Gilead’s long-acting HIV treatment pipeline, particularly its lenacapavir-based combinations, is well-positioned to meet the growing demand for longer-acting treatment options. These developments, coupled with the recent patent extension for Biktarvy, enhance the company’s market prospects and provide a solid foundation for future growth. Despite some uncertainties related to pricing, these are considered to be factored into the current valuation, making Gilead an attractive investment opportunity.
In another report released on October 23, TD Cowen also maintained a Buy rating on the stock with a $125.00 price target.